These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 14532842

  • 1. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH.
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [Abstract] [Full Text] [Related]

  • 2. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model.
    de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH.
    Eur Urol; 2005 Aug; 48(2):333-8. PubMed ID: 15963631
    [Abstract] [Full Text] [Related]

  • 3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 4. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S.
    Urol Int; 2005 Feb; 75(2):114-8. PubMed ID: 16123563
    [Abstract] [Full Text] [Related]

  • 5. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR, Drowart A, Van Vooren JP, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman CC, Huygen K.
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [Abstract] [Full Text] [Related]

  • 6. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study.
    de Boer EC, De Reijke TM, Vos PC, Kurth KH, Schamhart DH.
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S109-14. PubMed ID: 11010835
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF, Chang SY, Hsieh DS, Yu DS.
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [Abstract] [Full Text] [Related]

  • 8. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH, Frambach M, Deinert I, Brandau S, Jocham D, Böhle A.
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [Abstract] [Full Text] [Related]

  • 9. Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette-Guerin (BCG)-treated apolipoprotein E-knockout (apo E-/-) mice.
    Shibata Y, Ohata H, Yamashita M, Tsuji S, Bradfield JF, Nishiyama A, Henriksen RA, Myrvik QN.
    Transl Res; 2007 Feb; 149(2):62-9. PubMed ID: 17240316
    [Abstract] [Full Text] [Related]

  • 10. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).
    Saban MR, Simpson C, Davis C, Wallis G, Knowlton N, Frank MB, Centola M, Gallucci RM, Saban R.
    BMC Immunol; 2007 May 16; 8():6. PubMed ID: 17506885
    [Abstract] [Full Text] [Related]

  • 11. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
    Elsässer-Beile U, Gutzeit O, Bauer S, Katzenwadel A, Schultze-Seemann W, Wetterauer U.
    J Urol; 2000 Jan 16; 163(1):296-9. PubMed ID: 10604379
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug 16; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

  • 13. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
    Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W.
    J Urol; 2003 Nov 16; 170(5):2009-13. PubMed ID: 14532843
    [Abstract] [Full Text] [Related]

  • 14. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK.
    J Urol; 2001 Dec 16; 166(6):2142-7. PubMed ID: 11696723
    [Abstract] [Full Text] [Related]

  • 15. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin.
    Sander B, Skansén-Saphir U, Damm O, Håkansson L, Andersson J, Andersson U.
    Immunology; 1995 Dec 16; 86(4):512-8. PubMed ID: 8567014
    [Abstract] [Full Text] [Related]

  • 16. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb 16; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 17. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O'Donnell MA.
    Urology; 1998 Aug 16; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [Abstract] [Full Text] [Related]

  • 18. Effect of glutamine on Th1 and Th2 cytokine responses of human peripheral blood mononuclear cells.
    Chang WK, Yang KD, Shaio MF.
    Clin Immunol; 1999 Dec 16; 93(3):294-301. PubMed ID: 10600341
    [Abstract] [Full Text] [Related]

  • 19. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH.
    J Immunother; 2008 Jan 16; 31(1):34-42. PubMed ID: 18157010
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan 16; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.